Buy Jentadueto

Jentadueto

What is Jentadueto?

Jentadueto is a prescription-only combination pill that contains two active ingredients: linagliptin 2.5 mg and metformin hydrochloride 500 mg. It belongs to the therapeutic class of Diabetes Management medications and is indicated for adults with type 2 diabetes mellitus (T2DM) when diet, exercise, and monotherapy with either component are insufficient to achieve glycaemic control. In Hong Kong, Jentadueto is regulated by the Department of Health and is available only with a physician’s prescription.

How Jentadueto Works in the Body

Jentadueto combines two complementary mechanisms:

• Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. By blocking the DPP-4 enzyme, it prevents the rapid breakdown of incretin hormones (GLP-1 and GIP). Higher circulating incretins stimulate glucose-dependent insulin secretion, reduce glucagon release, and modestly slow gastric emptying. This lowers post-prandial blood glucose without causing hypoglycaemia when used alone.

• Metformin is a biguanide that primarily reduces hepatic glucose production (gluconeogenesis) and improves peripheral insulin sensitivity. It also modestly decreases intestinal glucose absorption. Metformin’s actions lead to lower fasting plasma glucose and modest weight neutrality.

Together, the drugs provide a dual approach: linagliptin targets post-meal spikes, while metformin lowers basal glucose output. The combined effect often results in greater overall reduction in glycated haemoglobin (HbA1c) than either agent alone.

Conditions Treated by Jentadueto

Jentadueto is approved by the Hong Kong Department of Health for the following indication:

• Type 2 diabetes mellitus in adults, as an adjunct to diet and exercise, when monotherapy with either linagliptin or metformin does not provide adequate glycaemic control.

The medication is not indicated for type 1 diabetes, diabetic ketoacidosis, or gestational diabetes. Use should be based on an individualized assessment by a qualified healthcare professional.

Patient Suitability and Contraindications

Who Should Use Jentadueto?

• Adults with diagnosed T2DM who need additional glucose-lowering beyond diet, exercise, and a single oral agent.
• Patients with adequate renal function (eGFR ≥ 60 mL/min/1.73 m²) because metformin accumulation can occur in reduced kidney function.
• Individuals who can tolerate metformin’s gastrointestinal (GI) profile.

Absolute Contraindications

• Known hypersensitivity to linagliptin, metformin, or any inactive ingredient in the pill.
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²) or patients receiving dialysis.
• Acute metabolic acidosis, including diabetic ketoacidosis, with or without coma.
• Concomitant use of other medicinal products containing metformin (to avoid overdose).

Relative Contraindications

• Moderate renal impairment (eGFR 30-45 mL/min/1.73 m²): dose adjustment and close monitoring required.
• Hepatic disease: metformin is cleared unchanged, but severe liver dysfunction may affect overall metabolic status.
• History of lactic acidosis.
• Pregnancy or breastfeeding: metformin is generally considered safe, but linagliptin lacks sufficient data; use only if benefits outweigh potential risks.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Gastrointestinal upset (nausea, diarrhoea, abdominal discomfort) - frequently reported with metformin.
• Upper respiratory tract symptoms (nasal congestion, sore throat) - more commonly linked to linagliptin.
• Headache - mild and transient.

These effects are usually mild, self-limiting, and may improve with continued use or dose titration.

Serious Adverse Events

• Lactic acidosis - a rare but life-threatening condition associated with metformin accumulation, especially in renal impairment.
• Severe hypersensitivity reactions (e.g., rash, angio-edema, anaphylaxis) - require immediate medical attention.
• Pancreatitis - occasional reports with DPP-4 inhibitors; monitor for persistent abdominal pain.

If any of the following symptoms appear-persistent abdominal pain, unexplained fatigue, rapid breathing, or swelling-seek emergency care.

Drug Interactions

• Cimetidine, trimethoprim, or loop diuretics may increase metformin plasma concentrations, raising the risk of lactic acidosis.
• Iodinated contrast agents used in radiographic imaging can temporarily impair renal function; metformin should be discontinued at least 48 hours before and resumed only after confirming normal renal function.
• Strong CYP3A4 inhibitors/inducers have minimal effect on linagliptin, which is predominantly excreted unchanged; however, clinicians should still assess for any potential interaction.
• Other antidiabetic agents (sulfonylureas, insulin) may increase the risk of hypoglycaemia when combined with linagliptin; dose adjustments may be needed.

Food and Lifestyle Interactions

• Food: Metformin absorption is slightly reduced when taken with a high-fat meal; however, taking Jentadueto with meals helps minimise GI upset and improves tolerability.
• Alcohol: Excessive alcohol intake can increase the risk of lactic acidosis; limit consumption and discuss safe limits with a healthcare provider.
• Driving: Neither linagliptin nor metformin is known to impair cognition or coordination; standard cautions for any medication apply.

If you are taking over-the-counter supplements, herbal products, or other prescription drugs, inform your prescriber before starting Jentadueto.

Dosing and Administration Guidelines

• Standard starting dose: One pill (2.5 mg linagliptin / 500 mg metformin) taken once daily with the first main meal of the day. Swallow the tablet whole; do not split, chew, or crush.
• Titration: If glycaemic targets are not met after 4-6 weeks, the prescriber may increase the dose to the next available strength (e.g., 5 mg/1000 mg) provided renal function remains adequate.
• Renal adjustment: For eGFR 30-45 mL/min/1.73 m², the maximum recommended dose is typically limited to 1,000 mg metformin per day; clinicians may maintain the 2.5 mg linagliptin dose.
• Missed dose: Take the missed pill with the next meal. Do not double the dose to compensate.
• Overdose: Symptoms may include severe GI upset, lactic acidosis, or hypoglycaemia (if combined with other glucose-lowering agents). Seek emergency medical care; dialysis may be required for metformin toxicity.
• Discontinuation: No tapering is required for linagliptin. Metformin can be stopped abruptly, but abrupt cessation may cause a temporary rise in blood glucose; monitor HbA1c and glucose levels after discontinuation.

Monitoring and Follow-Up

• HbA1c: Measure at baseline, then every 3 months after initiating or adjusting therapy.
• Renal function: Check serum creatinine and eGFR prior to starting treatment and at least annually, or more frequently if renal function is borderline.
• Liver enzymes: Routine monitoring is not required unless clinical suspicion exists.
• Blood glucose logs: Encourage patients to record fasting and post-prandial values to aid dose optimization.

Regular follow-up visits enable timely identification of adverse effects and assessment of therapeutic effectiveness.

Storage and Handling

• Store the tablets at room temperature (15-30 °C), protected from moisture and direct sunlight.
• Keep the medication out of reach of children and pets.
• Do not use the product after the expiration date printed on the packaging.
• Dispose of unused tablets according to local pharmacy waste guidelines or the “Return-to-Pharmacy” programme in Hong Kong.

Medication-Specific Glossary

DPP-4 Inhibitor

A class of drugs that block the dipeptidyl peptidase-4 enzyme, prolonging the activity of incretin hormones and enhancing insulin secretion after meals.

Biguanide

A pharmacologic group that includes metformin; it primarily reduces hepatic glucose production and improves insulin sensitivity.

eGFR (estimated Glomerular Filtration Rate)

A calculated measure of kidney function that helps determine safe dosing of renally excreted drugs.

Lactic Acidosis

A rare but serious metabolic complication characterized by elevated lactate levels and low blood pH, potentially fatal if untreated.

Medical Disclaimer

This article provides educational information about Jentadueto and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.